Speakers

Melanoma   |   Multiple Myeloma   |   RCC   |   Lung   |   Colorectal Cancer   |   Industry


Michael A. Davies, MD, PhD

Associate Professor, Department of Melanoma Medical Oncology

MD Anderson Cancer Center

Dr. Davies earned his medical and doctorate degrees from the University of Texas Health Science Center in Houston. He completed his clinical residency training in internal medicine at the Massachusetts General Hospital, and his medical oncology fellowship at the University of Texas MD Anderson Cancer Center. Dr. Davies is currently an associate professor in the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, with a joint appointment in the Department of Systems Biology. Dr. Davies is a physician-scientist whose research utilizes integrated approaches to study the regulation and clinical significance of protein kinase signaling pathways in cancer. Dr. Davies has made several key insights in the role of the PI3K-AKT pathway in melanoma, including the identification of disease-specific mutations in AKT isoforms, differential activation of the pathway in different metastatic sites, and compensatory pathway activation as a mechanism of resistance to MAPK pathway inhibitors. Dr. Davies has led or co-led several clinical trials, including the testing of targeted therapies in patients with brain metastases from melanoma. Dr. Davies has published peer-reviewed articles in a variety of journals, including Cancer Cell, Lancet Oncology, Cancer Research, Clinical Cancer Research, Molecular Cancer Therapeutics, and Cancer. He is the principal investigator of R01 grants from NCI and the Cancer Prevention Research Institute of Texas; Young Investigator and Career Development Awards from American Society for Clinical Oncology (ASCO); and he is the multi-center PI of a 2013 Team Science Grant from the Melanoma Research Foundation (MRA). Dr. Davies is a member of the Melanoma Research Foundation Breakthrough Consortium, and the co-director of the MD Anderson Melanoma Moon Shot Team and the MD Anderson

Targeted Therapy in Melanoma



Kenneth Anderson, MD

Kraft Family Professor of Medicine

Harvard Medical School

Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. After graduating from Johns Hopkins Medical School, he trained in internal medicine at John’s Hopkins Hospital, and then completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Over the last three decades, he has focused his laboratory and clinical research studies on multiple myeloma. He has developed laboratory and animal models of the tumor in it is microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies, and has then rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted therapies. His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome. He is the recipient of many scientific and humanitarian awards including the International Myeloma Workshop Waldenstrom’s Award in 2003, the International Myeloma Foundation Robert A. Kyle Lifetime Achievement Award in 2005, the American Association for Cancer Research Joseph H. Burchenal Award in 2007, and the American Society of Hematology William Dameshek Prize in 2008. He was elected into the Johns Hopkins Society of Scholars in 2009, the Institute of Medicine of the National Academy of Sciences in 2010, and the Royal College of Physicians and of Pathologists (UK) in 2010. In 2011 he received the American Society of Clinical Oncology David A. Karnofsky Award and the Hope Funds for Cancer Research Award of Excellence in Clinical Research, and in 2012 received the Ron Burton Humanitarian Award, the Harvard Medical School Warren Alpert Foundation Prize, and the American Cancer Society Medal of Honor.

Integrating New Therapies into the Treatment of Newly Diagnosed MM

Controversies in the Management of Relapsed/Refractory MM


Philip McCarthy, MD

Professor of Oncology

Roswell Park Cancer Institute

Dr. McCarthy is the Director of the Blood and Marrow Transplantation (BMT) Program at Roswell Park Cancer Institute (RPCI) and a Professor of Oncology. Dr. McCarthy has been a BMT Physician and Hematologist/Oncologist since finishing fellowship training in 1989. He has been the BMT Director at RPCI since 1997. He is a member of the Cancer and Leukemia Group B (CALGB) cooperative clinical trials group, the Center for Institutional Research on Blood and Marrow Transplantation (CIBMTR) as well as a member of the editorial boards of two BMT journals. He has been a clinical investigator in oncology, particular BMT, for more than 20 years. He has served as chair, or co-chair, of several clinical trials, including CALGB 100104, a phase III clinical trial evaluating lenalidomide maintenance after autologous hematopoietic cell transplant (HCT) for multiple myeloma. He is a member of the protocol team for the ongoing BMT Clinical Trials Network (CTN) study: A Trial Single Autologous Transplant with or without RVD Consolidation versus Tandem Transplant and Maintenance Therapy for Patients with Multiple Myeloma. Dr. McCarthy is a member of the American Society of Hematology and the American Society of Clinical Oncology. His research interests are devoted to developing novel myeloablative and non-myeloablative autologous and allogeneic BMT treatments of hematologic disorders that will lead to improved patient outcomes and decreased toxicity.

Integrating New Therapies into the Treatment of Newly Diagnosed MM

Controversies in the Management of Relapsed/Refractory MM



Sumanta Kumar Pal, MD

Assistant Professor, Department of Medical Oncology & Therapeutics Research

City of Hope

Sumanta Kumar Pal, M.D., is an assistant professor in the Department of Medical Oncology & Therapeutics Research and co-director of the Kidney Cancer Program at City of Hope. Having been appointed to the faculty for just over four years, Dr. Pal has been extremely productive, publishing more than 85 manuscripts in peer-reviewed journals. He has presented his work in multiple international meetings. Dr. Pal began his college career at the age of 13 through the California State University, Los Angeles Early Entrance Program. He began medical school at the age of 17 at the University of California, Los Angeles (UCLA), where he developed an immediate interest in cancer research. Working in the laboratory of Dennis Slamon, M.D., Ph.D., Dr. Pal examined the breast cancer drug trastuzumab, performing laboratory-based studies to elucidate mechanisms of resistance to the agent. He continued this work during the course of his residency training at UCLA.
After completing his residency, Dr. Pal transitioned to City of Hope where he trained under Robert Figlin, M.D., developing clinical trials and translational studies for genitourinary cancer, principally in the domain of renal cell carcinoma and prostate cancer. He has garnered numerous awards to support his work, including grants from the California Breast Cancer Research Program, the National Comprehensive Cancer Network and the National Institutes of Health. He recently received a Young Investigator Award from the Kidney Cancer Association to recognize his outstanding research in this domain, and further received the 2012 Charles A. Coltman Translational Research Award from the Southwest Oncology Group to support his work in bladder cancer.
Dr. Pal’s vision is to take discoveries made in the laboratory and translate these findings as quickly and efficiently as possible into tangible benefits for patients.

Strategies for Minimizing Toxicities in Patients Undergoing Treatment for RCC





Jyoti Patel, MD

Associate Professor of Medicine

Northwestern University Feinberg School of Medicine

Dr Patel is Associate Professor of Medicine at the Feinberg School of Medicine of Northwestern University. She specializes in the treatment of lung cancer. In addition to developing novel therapies for lung cancer, she has a special interest in lung cancer in women and the interplay of genetic, hormonal, and molecular differences that contribute to differences in outcome in women. She graduated from Northwestern University with a degree in English Literature and received her MD from Indiana University. She then completed residency at Northwestern University, where she also served as Chief Medical Resident. She completed medical oncology fellowship at Memorial Sloan-Kettering Cancer Center. In 2003 she returned to Northwestern, and Dr Patel now serves as the Thoracic Oncology Program Leader of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. She has authored numerous publications and has served as the principal investigator of multiple clinical trials. She is Co-Chair of the Thoracic Committee of the Hoosier Oncology Group. She has is a member of the core committee of the Thoracic Committee of the Eastern Cooperative Oncology Group. She is a member of the NCCN Non-Small Cell Lung Cancer and Small Cell Lung Cancer Panels. She has served on the Scientific Program Committees of ASCO and IASLC. She was awarded the Early Career Achievement Award from Indiana University School of Medicine. She was also part of ASCO’s prestigious Leadership Development Program.

Advancing Personalized Care for Patients with NSCLC: Tumor Genotyping and Biomarkers

Advances in Targeted Therapy for NSCLC





John L. Marshall, MD

Professor and Chief, Division of Hematology/Oncology

Georgetown University Hospital









Forgot Password Click Here to Register